Tell your health care provider right away if you have any new or worsening symptoms, including: KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. KISQALI may cause serious side effects, including: What is the most important information I should know about KISQALI? It is not known if KISQALI is safe and effective in children. fulvestrant as the first endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.an aromatase inhibitor as the first endocrine-based therapy or.KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with: This offer is available for patients with a valid prescription for the KISQALI FEMARA Co-Pack, or for KISQALI and/or FEMARA (including generic letrozole), including for patients who have not been prescribed KISQALI or another Novartis product. ‡No purchase required of the KISQALI FEMARA Co-Pack, or KISQALI or FEMARA (including generic letrozole). It is not known if KISQALI or the KISQALI FEMARA Co-Pack are safe and effective in children. The yellow tablet contains the medicine FEMARA® (letrozole).The violet tablet contains the medicine KISQALI® (ribociclib).The KISQALI FEMARA Co-Pack contains 2 different types of medicines: The KISQALI® (ribociclib) FEMARA® (letrozole) Co-Pack is a prescription medicine used as the first hormonal-based therapy to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).
XOLAIR CO PAY CARD FREE
‡Ĭall 1-80 or visit to receive your free treatment voucher. Patients are eligible to receive a 1-treatment cycle supply of any one of the following at no cost.
To find out if you are eligible for the Novartis Oncology Universal Co-Pay Program, call 1-87 or visit .ġ FREE Treatment Cycle of KISQALI and/or FEMARA
XOLAIR CO PAY CARD FULL
For full terms and conditions, visit or call 1-87. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer is NOT valid for purchases of FEMARA only by California or Massachusetts residents. Use of this offer for FEMARA (or generic letrozole) does not require a KISQALI prescription. The Program is NOT AVAILABLE for patients that are enrolled in Medicare, Medicaid, or any other federal or state health care program. This offer is only available to patients with private insurance. Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product.Eligible patients with private insurance may pay $0 per month †.You may be eligible for immediate co-pay savings on your next prescription of KISQALI and/or FEMARA (including generic letrozole). Offer is NOT valid for purchases of FEMARA only by Massachusetts patients or for California patients that do not meet additional eligibility criteria.
Patients with commercial insurance who are still waiting for their coverage to take effect for the KISQALI FEMARA Co-Pack or KISQALI may be eligible for an additional supply of KISQALI that could continue for up to 5 treatment cycles.*įor more information, talk to your doctor or call 1-80 to speak to one of our Patient Navigators.
0 kommentar(er)
